ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of UnitedHealthcare's updated medical policy (#2024T0525NN) for Obstructive and
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program.
Compugen shares jumped 204.1% to $2.22 on Tuesday.
ProSomnus Inc (NASDAQ: OSA) announced the publication of a study by the Cureus Journal of Medical Science, highlighting the company's precision oral appliance therapy (OAT) devices for
ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, today announced the publication of a study by the Cureus Journal of Medical Science, in which the